Thrivent Financial for Lutherans Purchases 33,878 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Thrivent Financial for Lutherans increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 111.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 64,211 shares of the company’s stock after buying an additional 33,878 shares during the period. Thrivent Financial for Lutherans owned about 0.06% of Intellia Therapeutics worth $749,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Commonwealth Equity Services LLC increased its stake in Intellia Therapeutics by 26.0% in the 4th quarter. Commonwealth Equity Services LLC now owns 30,764 shares of the company’s stock worth $359,000 after acquiring an additional 6,343 shares during the last quarter. Swiss National Bank raised its stake in Intellia Therapeutics by 6.0% during the fourth quarter. Swiss National Bank now owns 189,700 shares of the company’s stock valued at $2,212,000 after purchasing an additional 10,700 shares in the last quarter. Wealthfront Advisers LLC bought a new position in Intellia Therapeutics during the fourth quarter valued at $263,000. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Intellia Therapeutics in the 4th quarter worth $43,177,000. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Intellia Therapeutics by 80.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after buying an additional 2,299 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 28,444 shares of company stock valued at $345,862. 3.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $56.00 to $11.00 in a report on Monday, January 27th. Wedbush reissued a “neutral” rating and issued a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. HC Wainwright assumed coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Citigroup raised their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $7.30 on Thursday. The stock has a fifty day moving average price of $9.79 and a 200 day moving average price of $13.48. Intellia Therapeutics, Inc. has a 1-year low of $6.50 and a 1-year high of $28.18. The company has a market cap of $755.67 million, a PE ratio of -1.34 and a beta of 2.23.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.